发明名称 USE OF ACTIVIN RECEPTOR-LIKE KINASE 1 (ALK-1) ANTAGONISTS IN THE TREATMENT OF CANCER
摘要 Some aspects of this disclosure provide methods and compositions for the treatment of cancer, for example, head and neck cancer, in a subject using ALK1 inhibitors, e.g., ALK1-ECD polypeptides, ALK1-Fc fusion proteins, or ALK1-inhibitory antibodies. In some embodiments, methods and compositions are provided for treating certain cancers with ALK1 inhibitors in combination with a chemotherapeutic platinum agent. In some embodiments, methods are provided for identifying whether a cancer in a subject will react to treatment with an ALK1 antagonist, either alone or in combination with a chemotherapeutic platinum agent, for example, based on a determination that the cancer or the subject is positive for human papilloma virus.
申请公布号 US2015299677(A1) 申请公布日期 2015.10.22
申请号 US201514671064 申请日期 2015.03.27
申请人 Acceleron Pharma, Inc. 发明人 Alimzhanov Marat B.;Pandya Shuchi Sumant
分类号 C12N9/12;A61K38/45;A61K39/395;C12Q1/70;A61K33/24 主分类号 C12N9/12
代理机构 代理人
主权项 1. A method of treating head and neck cancer in a subject, the method comprising administering to a subject in need thereof (a) an agent selected from the group consisting of (i) an ALK1-extracellular domain (ALK1-ECD) polypeptide;(ii) an antibody that binds to an ALK1 polypeptide comprising amino acids 22-118 of SEQ ID NO: 1; or(iii) an antibody that binds to BMP9 or BMP10; and (b) a chemotherapeutic platinum agent;in an amount sufficient to treat the head and neck cancer in the subject.
地址 Cambridge MA US